MaxCyte Signed a Non-Exclusive License Agreement with Vertex to Advance CTX001 Transfusion-Dependent Beta Thalassemia or Sickle Cell Disease
Shots:
- Vertex gets the non-exclusive clinical & commercial rights to use MaxCyte’s Flow Electroporation technology & ExPERT platform to develop exa-cel, CTX001 for hemoglobinopathies while MaxCyte will receive platform licensing fees & program-related revenue
- ExPERT platform can be used across the high-growth cell therapy sector from discovery and development & to commercialization of cell-based therapies. It has been developed to support the quickly growing cell therapy business
- Exa-cel is an ex vivo CRISPR gene-edited cell therapy & is currently being studied in the P-II/III study. The therapy is indicated for the treatment of TDT or SCD characterized by recurrent vaso-occlusive crises
Ref: Globenewswire | Image: MaxCyte
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
